Comparative Pharmacology
Head-to-head clinical analysis: CETRORELIX ACETATE versus DEGARELIX ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETRORELIX ACETATE versus DEGARELIX ACETATE.
CETRORELIX ACETATE vs DEGARELIX ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) antagonist. Competitively blocks GnRH receptors on pituitary gonadotropes, inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Gonadotropin-releasing hormone (GnRH) receptor antagonist; competitively and reversibly binds to GnRH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
250 mcg subcutaneously once daily, starting on day 7 of ovarian stimulation and continuing until the day of hCG administration. Alternatively, a single 3 mg subcutaneous dose on day 7 of stimulation if hCG is given on day 9.
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
None Documented
None Documented
Terminal elimination half-life: ~7-9 hours in healthy adults; prolonged to ~14-30 hours in patients with hepatic or renal impairment (clinical significance: no dose adjustment needed for mild-to-moderate renal or hepatic impairment, but caution in severe cases due to potential accumulation).
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
Primarily renal (excreted unchanged in urine ~42% within 24 hours; total urinary recovery ~66-69% over 8 days); biliary/fecal elimination accounts for <5%.
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
Category C
Category C
GnRH antagonist
GnRH antagonist